Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-209 plus fulvestrant versus placebo plus fulvestrant in endocrine-resistant HR-positive/HER2-negative advanced breast cancer
ChiCTR2200059458Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bebt-209 and fulvestrant in breast cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
bebt-209fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200059458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059458.